Rocky Swift
Stories by Rocky Swift
Blackstone, Taisho Pharma said to be among final bidders for Takeda’s Japan OTC unit
The deal size could be around $3.7 billion.
Japan’s Takeda plans to sell consumer health unit for around $3.7b
Possible buyers of the unit include Taisho Pharmaceutical Co. and large investment funds.
Japan’s Astellas Pharma maintains full-year profit forecast amid overseas M&A
The company said it expects an operating profit of $2.40 billion for the year ending March 31.
Japan’s Astellas Pharma buys US biotech Xyphos for $665m
Japanese firms have signed over 30 overseas deals worth about $6 billion in the healthcare sector this year.
Japan’s Astellas to buy US-based Audentes for $3b in gene therapy push
Astellas is offering $60 per share for Audentes, a 110% premium to its closing price on Monday.
Mitsubishi Chem to spend $4.5b to acquire rest of Mitsubishi Tanabe
The chemical maker already held more than 56% of shares in Mitsubishi Tanabe.
After WeWork debacle, SoftBank boss Son to adopt cautious IPO course
Vision Fund would now look to see companies list when they were closer to achieving profitability.
Japan’s Sumitomo Pharma to invest $3b for 10% stake in Swiss Roivant
The deal will also give it the option to acquire interests in an additional six businesses.
